StemCell Therapy

Syros Pharmaceuticals Inc (SYRS) is near the middle in its industry group according to InvestorsObserver. SYRS gets an overall rating of 57. That means it scores higher than 57 percent of stocks. Syros Pharmaceuticals Inc gets a 65 rank in the Biotechnology industry. Biotechnology is number 26 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 57 means the stock is more attractive than 57 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Syros Pharmaceuticals Inc (SYRS) stock is down -2.84% while the S&P 500 is higher by 0.33% as of 2:23 PM on Friday, Aug 28. SYRS has fallen -$0.38 from the previous closing price of $13.39 on volume of 312,289 shares. Over the past year the S&P 500 is up 19.54% while SYRS is higher by 18.60%. SYRS lost -$1.69 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Syros Pharmaceuticals Inc click here.

Go here to see the original:
Is Syros Pharmaceuticals Inc (SYRS) the Top Pick in the Biotechnology Industry? - InvestorsObserver

This entry was posted on August 28, 2020 at 11:55 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |